Group items tagged

To improve early detection and treatment of cancer, a pair of Toronto scientists, Dr David Jaffray, a senior scientist in the division of biophysics and bioimaging at the Ontario Cancer Institute and Dr Christine Allen, an associate professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto has developed a technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Dec 23, 2009

MaRS Centre cleared after potentially dangerous substance was discovered in the Toronto Medical Discoveries Tower. UHN officials will revisit the incident and decide whether internal proceedures need to be changed.

MaRS Centre cleared after potentially dangerous substance was discovered in the Toronto Medical Discoveries Tower. UHN officials will revisit the incident and decide whether internal proceedures need to be changed.

MaRS Centre cleared after potentially dangerous substance was discovered in the Toronto Medical Discoveries Tower. UHN officials will revisit the incident and decide whether internal proceedures need to be changed.

A pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Nov 20, 2009

A pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Nov 19, 2009

DLVR Therapeutics Inc. ("DLVR") - a privately-held biotechnology company announced it completed its seed round investment. University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) are investors in the company.